'Unconvincing' two-year data for newly approved Eylea
05 December 2011
Pial Ganguli
Please Login to read the full article.
05 December 2011
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- CATT 2-year results add fuel to Avastin/Lucentis debate, with implications for Eylea
- FDA panel backs Regeneron wet AMD drug, all eyes on pricing
- Narrowing price gap may not make Roche's Lucentis more attractive than Eylea
- Regeneron's Eylea wins US OK; bests Lucentis in pricing, dosing
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
